Novimmune Sa

Nordmark Arzneimittel Gmbh & Co. Kg

Thierry Berney

Marie Kosco-Vilbois

Katrien De Graaf

Domenic Bosco

Olaf Friedrich

Daniel Brandhorst

Christian Raemsch

Heide Brandhorst

Pascal Bucher

Silke Huettler

Nicole Raemsch-Guenther

Laurianne Santa Giovannoni

Manfred Kurfürst

Manfred Kurfuerst

Santa Giovannoni

Katrien L De Graaf

Domenico Bosco

Nicole Raemsch-Guenter

This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.

Anti-TLR4 antibodies and uses thereof

Anti-TLR4 antibodies and methods of use thereof

The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.

Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof

The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.

Growing community of inventors

Arenthon, France

Thierry Berney